✦ LIBER ✦

Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401)

✍ Scribed by Shien, Tadahiko; Iwata, Hiroji; Aogi, Kenjiro; Fukutomi, Takashi; Inoue, Kenichi; Kinoshita, Takayuki; Takahashi, Masato; Matsui, Akira; Shibata, Taro; Fukuda, Haruhiko

Book ID: 121579358
Publisher: Springer
Year: 2014
Tongue: English
Weight: 307 KB
Volume: 19
Category: Article
ISSN: 1341-9625
DOI: 10.1007/s10147-013-0657-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tamoxifen plus tegafur-uracil (TUFT) ver

Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404

✍ Tadahiko Shien,Hiroji Iwata,Takashi Fukutomi… 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 558 KB

Uracil-tegafur and tamoxifen versus cycl

Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study

✍ Park, Y; Okamura, K; Mitsuyama, S; Saito, T; Koh, J; Kyono, S; Higaki, K; Ogita, 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 44 KB

396 Randomized controlled study comparin

396 Randomized controlled study comparing surgery alone, surgery plus tamoxifen, and surgery plus tegafur-uracil in patients with node-negative breast cancer: 5-year results from the Kanto cooperative study group of adjuvant chemo-endocrine therapy for breast cancer (ACETBC) of Japan

✍ M. Kusama; T. Ikeda; K. Enomoto; F. Kasumi; T. Tominaga; S. Haga; M. Fukuda; S. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Comparison of Doxorubicin and Cyclophosp

Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)

✍ Shulman, L. N.; Berry, D. A.; Cirrincione, C. T.; Becker, H. P.; Perez, E. A.; O 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 202 KB

Design, conduct, and analyses of Breast

Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer

✍ Giobbie-Hurder, A.; Price, K. N; Gelber, R. D 📂 Article 📅 2009 🏛 SAGE Publications 🌐 English ⚖ 194 KB

First results of a randomized phase III

First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group

✍ R Paridaens; P Therasse; L Dirix; L Beex; M.J Piccart; D Cameron; T Cufer; K Roo 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 172 KB